Breast Cancer New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer Ulas D. Bayraktar, MD 2023-03-15
Ovarian Cancer New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer Ulas D. Bayraktar, MD 2023-01-10
Melanoma New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma Ulas D. Bayraktar, MD 2023-01-10
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for R/R CLL Ulas D. Bayraktar, MD 2023-01-10
Hepatocellular Carcinoma New Protocol: Tremelimumab and Durvalumab for HCC Ulas D. Bayraktar, MD 2023-01-10
Follicular Lymphoma New Drug: Mosunetuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-01-10
